Literature DB >> 27130457

Polymorphisms of the Stem Cell Marker Gene CD133 and the Risk of Lung Cancer in Chinese Population.

Qing-Feng Liu1, Zhi-Fei Zhang1, Guang-Jie Hou1, Guang-Yu Yang1, Yi He2.   

Abstract

OBJECTIVE: To explore the association of functional single-nucleotide polymorphisms (SNPs) of CD133 with the risk of lung cancer.
METHODS: We conducted a hospital-based, case-control study of 1017 lung cancer patients and 1035 cancer-free controls frequency-matched by age and sex. Four functional CD133 SNPs (rs2240688 A > C, rs10022537 T > A, rs7686732 C > G, and rs3130 C > T) were selected and genotyped. Unconditional univariate and multivariate logistic regression analyses were carried out to evaluate the associations of genotypes of CD133 SNPs with lung cancer risk.
RESULTS: Compared with rs2240688 AA genotype, the variant AC/CC genotypes were associated with a statistically increased risk of lung cancer under a recessive model (adjusted odds ratio 1.19; 95 % confidence interval 1.01-1.42). The risk remained in patients with other histology types, but not with adenocarcinoma and squamous cell cancers.
CONCLUSIONS: These findings suggest that SNP rs2240688 A > C of CD133 may be a potential biomarker for genetic susceptibility to lung cancer, but require further research with larger populations.

Entities:  

Keywords:  CD133 polymorphism; China; Genetic susceptibility; Lung cancer

Mesh:

Substances:

Year:  2016        PMID: 27130457     DOI: 10.1007/s00408-016-9876-1

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  23 in total

Review 1.  Global patterns of cancer incidence and mortality rates and trends.

Authors:  Ahmedin Jemal; Melissa M Center; Carol DeSantis; Elizabeth M Ward
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

2.  A risk model for prediction of lung cancer.

Authors:  Margaret R Spitz; Waun Ki Hong; Christopher I Amos; Xifeng Wu; Matthew B Schabath; Qiong Dong; Sanjay Shete; Carol J Etzel
Journal:  J Natl Cancer Inst       Date:  2007-05-02       Impact factor: 13.506

3.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

4.  Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and β-catenin, in primary lung adenocarcinoma--their prognostic significance.

Authors:  Koji Okudela; Tetsukan Woo; Hideaki Mitsui; Michihiko Tajiri; Munetaka Masuda; Kenichi Ohashi
Journal:  Pathol Int       Date:  2012-12       Impact factor: 2.534

5.  Survey of autoantibody responses against tumor-associated antigens in thyroid cancer.

Authors:  A Abols; K Ducena; P Zayakin; K Silina; Z Kalnina; L Sadovska; J Tars; J Vilmanis; Z Narbuts; J Eglitis; V Pirags; A Line
Journal:  Cancer Biomark       Date:  2014       Impact factor: 4.388

6.  Genomic characterization of esophageal squamous cell carcinoma from a high-risk population in China.

Authors:  Nan Hu; Chaoyu Wang; David Ng; Robert Clifford; Howard H Yang; Ze-Zhong Tang; Quan-Hong Wang; Xiao-You Han; Carol Giffen; Alisa M Goldstein; Philip R Taylor; Maxwell P Lee
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

Review 7.  Stem cell concepts renew cancer research.

Authors:  John E Dick
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

8.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Authors:  Giulia Bertolini; Luca Roz; Paola Perego; Monica Tortoreto; Enrico Fontanella; Laura Gatti; Graziella Pratesi; Alessandra Fabbri; Francesca Andriani; Stella Tinelli; Elena Roz; Roberto Caserini; Salvatore Lo Vullo; Tiziana Camerini; Luigi Mariani; Domenico Delia; Elisa Calabrò; Ugo Pastorino; Gabriella Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-10       Impact factor: 11.205

9.  CD133 antigen expression in ovarian cancer.

Authors:  Gabriella Ferrandina; Enrica Martinelli; Marco Petrillo; Maria Grazia Prisco; Gianfranco Zannoni; Stefano Sioletic; Giovanni Scambia
Journal:  BMC Cancer       Date:  2009-07-07       Impact factor: 4.430

10.  CD133: a stem cell biomarker and beyond.

Authors:  Zhong Li
Journal:  Exp Hematol Oncol       Date:  2013-07-01
View more
  5 in total

1.  miR-367 stimulates Wnt cascade activation through degrading FBXW7 in NSCLC stem cells.

Authors:  Guodong Xiao; Boxiang Zhang; Jinying Meng; Jichang Wang; Chongwen Xu; Shou-Ching Tang; Xiang Li; Jing Zhang; Rui Liang; Hong Ren; Xin Sun
Journal:  Cell Cycle       Date:  2017-11-14       Impact factor: 4.534

2.  Polymorphisms of the stem cell marker gene CD133 are associated the clinical outcome in a cohort of Chinese non-small cell lung cancer patients.

Authors:  Qing-Feng Liu; Zhi-Fei Zhang; Guang-Jie Hou; Guang-Yu Yang; Yi He
Journal:  BMJ Open       Date:  2017-08-21       Impact factor: 2.692

3.  Gene Combination of CD44 rs187116, CD133 rs2240688, NF-κB1 rs28362491 and GSTM1 Deletion as a Potential Biomarker in Risk Prediction of Breast Cancer in Lower Northern Thailand.

Authors:  Kamonpat Sapcharoen; Phanchana Sanguansermsri; Sukkid Yasothornsrikul; Kanha Muisuk; Metawee Srikummool
Journal:  Asian Pac J Cancer Prev       Date:  2019-08-01

4.  Silencing TRIM37 inhibits the proliferation and migration of non-small cell lung cancer cells.

Authors:  Yi Ding; Yi Lu; Xinjie Xie; Bo Sheng; Zuopei Wang
Journal:  RSC Adv       Date:  2018-10-31       Impact factor: 3.361

5.  SNP rs2240688 in CD133 gene on susceptibility and clinicopathological features of hepatocellular carcinoma.

Authors:  Xiaolan Pan; Lingsha Huang; Dan Mo; Yihua Liang; Zhaodong Huang; Bo Zhu; Min Fang
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.